What we do
iQone Healthcare Switzerland has a solid and growing portfolio of biosimilars and other therapeutic advances, and we take a fast and flexible approach to distributing them in Switzerland. We source our products from leading manufacturers around the world and provide them – together with tailored support services – to healthcare professionals all over the country.
Truxima® is a biosimilar monoclonal antibody designed to target the CD20 antigen. It was developed by Celltrion Healthcare for use in oncology, hematology and rheumatology, and received market approval in Switzerland in 2019. It is a Class A drug that must be stored between 2°C and 8°C. Truxima® is administered intravenously.
Truxima-rituximab 100mg and 500mg
Grasustek® is a biosimilar granulocyte colony stimulating factor used in oncology. Developed by USV Private Limited, it was approved for sale in Switzerland in 2021. It is a Class A drug that must be stored between 2°C and 8°C. Grasustek® can be self-administered subcutaneously.
Herzuma® is a biosimilar monoclonal antibody designed to target HER2. It was developed by Celltrion Healthcare for use in oncology and received market approval in Switzerland in 2021. It is a Class A drug that must be stored between 2°C and 8°C. Herzuma® is administered intravenously.
Herzuma-trastuzumab 150mg and 440mg
Services for healthcare providers
We provide you with everything you need to know about our products so that you can properly inform and treat your patients: how the products are manufactured and shipped, indications, potential side effects, storage and use, training and documentation, and ongoing support. We answer your questions, find solutions and deliver on what we promise.